Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Myriad Genetics stock

MYGN
US62855J1043
897518

Price

14.43
Today +/-
-0.07
Today %
-0.48 %

Myriad Genetics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Myriad Genetics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Myriad Genetics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Myriad Genetics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Myriad Genetics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Myriad Genetics Stock Price History

DateMyriad Genetics Price
12/13/202414.43 undefined
12/12/202414.50 undefined
12/11/202414.51 undefined
12/10/202415.34 undefined
12/9/202414.88 undefined
12/6/202415.13 undefined
12/5/202416.36 undefined
12/4/202416.60 undefined
12/3/202416.23 undefined
12/2/202416.69 undefined
11/29/202416.27 undefined
11/27/202416.27 undefined
11/26/202416.17 undefined
11/25/202415.70 undefined
11/22/202415.49 undefined
11/21/202415.12 undefined
11/20/202415.30 undefined
11/19/202415.00 undefined
11/18/202415.22 undefined
11/15/202415.25 undefined

Myriad Genetics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Myriad Genetics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Myriad Genetics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Myriad Genetics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Myriad Genetics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Myriad Genetics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Myriad Genetics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Myriad Genetics’s growth potential.

Myriad Genetics Revenue, EBIT and net profit per share

DateMyriad Genetics RevenueMyriad Genetics EBITMyriad Genetics Net Income
2028e1.14 B undefined112.76 M undefined89.15 M undefined
2027e1.08 B undefined86.26 M undefined67.79 M undefined
2026e989.01 M undefined63.71 M undefined37.2 M undefined
2025e905.63 M undefined26.58 M undefined11.41 M undefined
2024e857.59 M undefined20.93 M undefined12.27 M undefined
2023753.2 M undefined-136.9 M undefined-263.3 M undefined
2022678.4 M undefined-123.7 M undefined-112 M undefined
2021690.6 M undefined-126.7 M undefined-27.2 M undefined
2020299.8 M undefined-87.8 M undefined-53.1 M undefined
2019638.6 M undefined-132 M undefined-199.5 M undefined
2018851.1 M undefined31.7 M undefined4.6 M undefined
2017743.7 M undefined121.9 M undefined133.3 M undefined
2016728.7 M undefined44 M undefined17.4 M undefined
2015740.5 M undefined153.4 M undefined117.2 M undefined
2014723.1 M undefined134.2 M undefined80.2 M undefined
2013778.2 M undefined274.4 M undefined176.2 M undefined
2012613.2 M undefined228 M undefined147.1 M undefined
2011496 M undefined180.3 M undefined112.2 M undefined
2010402.1 M undefined157.8 M undefined100.7 M undefined
2009362.6 M undefined135.1 M undefined152.3 M undefined
2008326.5 M undefined126.5 M undefined84.6 M undefined
2007222.9 M undefined61.6 M undefined47.8 M undefined
2006145.3 M undefined32.3 M undefined-35 M undefined
2005100.6 M undefined13.9 M undefined-38.2 M undefined
200471.3 M undefined-4.2 M undefined-40 M undefined

Myriad Genetics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
000000.010.020.020.030.030.050.050.060.060.070.10.150.220.330.360.40.50.610.780.720.740.730.740.850.640.30.690.680.750.860.910.991.081.14
-----500.00150.0053.338.7036.0032.3517.7820.75-12.5026.7940.8545.0053.1046.8511.0411.0523.3823.5926.92-7.072.35-1.622.0614.54-25.03-53.13130.77-1.7411.0613.815.609.288.805.95
----100.00100.0093.3391.3088.0088.2482.2281.1379.6975.0071.8373.0078.6285.5986.8187.8588.3186.9086.9585.9979.5378.7876.5176.1876.3870.8569.5771.4570.2168.6660.3357.1352.2848.0545.35
0000161421223037435142517311419028331835543153366957558355756665045220849347651700000
000-3-5-5-9-9-10-8-7-14-24-40-40-38-35478415210011214717680117171334-199-53-27-112-2631211376789
----66.67-80.00-11.11-20.00-12.50100.0071.4366.67--5.00-7.89-234.2978.7280.95-34.2112.0031.2519.73-54.5546.25-85.47682.35-96.99-5,075.00-73.37-49.06314.81134.82-104.56-8.33236.3681.0832.84
3.84.611.316.417.730.435.637.237.640.445.647.351.554.761.475.486.493.498.699.291.786.583.378.274.573.468.8727674.3757880.682.800000
---------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Myriad Genetics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Myriad Genetics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                             
5.716.150.447.630.99.980.5127.273.172.8141.8113.8227.7214.1328.7316.9403.2346.5340.5372.3186.5144.8159150.7180.6136.9217.8150.7339.8114.9140.9
0000.20.51.32.45.47.213.11417.220.831.140.744.647.850.360.494.381.985.891.790.299.5133.968.189.591.3101.6114.3
00.10.10.30.11.90.40.40.39.20.51.21.41.44.70.70.30.52.72.73.21.93.35.73.84.72.92000
000000000000000008.211.6523.925.138.342.234.331.429.127.115.320.122
00.20.10.40.30.62.74.24.87.77.33.32.363.1422.712.77.39.726.92622.212.99.441.713.8120.138.43836.4
5.716.450.648.531.813.786137.285.4102.8163.6135.5252.2252.6377.2366.2474418.2422.5484322.4283.6314.5301.7327.6348.6331.7389.4484.8274.6313.6
13.29.41212.41011.312.715.418.717.318.519.824.93022.623.323.124.227.634.667.258.351.143.257.3103100.4125.3187.3180.6
0019.615.422.2298.218.751.253.500094.291.375.485.270.9113.7158.784.140.679.948.530.754.937215954.80
0000000000000000001921.700000000000
00.100.110.813.55.47.87.44.94.53.90.72.32.116.715.713.3205.3192.6227.5491.5455.2684.7605.3576.5404.1379.7349.5
0000000000000000056.156.956.9169.2177.2195.3316.1318.6417.2327.6329.2239.2286.8287.4
00000000000000009.425.938.641.68.25500002.38.315.515.4
000.030.030.040.040.020.030.070.080.020.020.020.120.120.10.120.190.270.320.50.480.570.910.851.211.071.030.840.920.83
0.010.020.080.080.070.050.110.170.160.180.190.160.280.380.50.470.590.610.690.80.820.770.881.211.181.561.41.421.321.21.15
                                                             
1001001001001002002002002003003003004004009001,000900900800800700700700700700700700800800800900
0.010.030.090.090.090.090.130.20.20.260.310.320.470.590.630.550.570.60.650.70.720.750.830.850.921.071.11.111.231.261.42
-3.8-9-14.9-24.1-33.9-43.9-52.7-59.8-73.8-98.7-139.3-179.2-217.4-252.4-204.6-119.9-10.5-38.6-12.730.92-77-73.2-78.254.125.6-173.9-227-254.2-366.2-629.5
0-1.5-1.9-1.4-0.6-0.3-0.10.40.30.7-0.2-0.5-0.7-0.4-0.22.80.10.2-0.2-0.4-1.5-7-9.5-5.5-4.1-5.4-5.2-2.3-5.1-8.9-3.7
00-0.10000000000000000000000000000
0.010.020.070.070.060.050.080.140.130.160.170.140.250.340.430.430.560.570.640.730.720.660.750.770.971.090.920.880.970.890.78
0.21.42.22.65.12.94.39.710.511.57.911.911.815.824.914.28.911.410.118.123.121.121.1222633.321.720.529.628.825.8
0.10.20.81.21.91.84.93.13.64.95.91114.91946.81818.621.632.844.356.446.137.344.449.548.860.970146.279.4104.8
0.10.85.75.72.70.719.519.814.431.20.30.10.42001.32.121.11.513.9151.126.735.764.455.428.52925.3
0000000000000000000000000000000
030030030010000000000000000000000000000
0.42.799.89.85.428.732.628.519.41523.226.835.273.732.227.534.34564.480.668.772.3217.5102.2117.8147145.9204.3137.2155.9
00.80.50.1000000000000000000099.19.3233.5224.4224.80038.5
0000000000000000000000.217.978.757.382.626.671.335.83.50
00000000000000008.89.61010.724.235.242.245.640.439.988.495.8112.8172.2168.9
00.80.50.10000000000008.89.61010.724.235.460.1223.4107356339.4391.9148.6175.7207.4
0.43.59.59.99.85.428.732.628.519.41523.226.835.273.732.236.343.95575.1104.8104.1132.4440.9209.2473.8486.4537.8352.9312.9363.3
0.010.020.080.080.070.050.110.170.160.180.190.160.280.380.50.470.590.610.690.80.820.770.881.211.181.561.41.421.321.21.15
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Myriad Genetics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Myriad Genetics's financial health and stability.

Assets

Myriad Genetics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Myriad Genetics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Myriad Genetics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Myriad Genetics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202020202120222023
00-3-5-5-9-9-10-8-7-14-24-40-40-38-35478415210011214717680117171314-199-53-27-112-263
00001233334556678977981325264854737266625261
000000000000000000-285333780130-2318-5544-32-30-4
0001500-7220-7-2716-1-1116-54-27-14-28-41-60-40-525-21-37115-128120-10110
000000000000244124569739427879122936425815472-69123124
000000000000000000000000000005001
00000000000000000039338010839321211611-8511
00-2-31-6-7-1417-3-16-46-30-23-28-25103841551301411731901401661061158360-7318-106-110
000-2-6-4-3-4-4-5-6-10-4-6-7-11-14-9-8-5-10-11-14-23-5-6-8-8-10-7-18-45-73
-5-50-2-5913-24-4-8538-12-3119-72-46-31-206-76-54-38-75-1740-91-146-11-2861928274-7731
-4-400-5217080-7944-1-2726-65-35-17-196-68-48-28-64-364-86-140-3-27729110292-32105
000000000000000000000000000000000
000100000000000000000000098-90225-80-226039
990155940038683595121491172184-49-175-103-88-222-180-68-2536-413-180-4114
9901658400386835951214911721-51-49-116-69-80-211-177-6871-95182-10-2-150-8152
00000000000000000-13605834711300-41-1-4-1-4-3-1
000000000000000000000000000000000
44-310110-9-950-20250-10-1494494-17429-403317-3904338-1770-46141-19274
-0.7-0.7-3.6-5.7-5-11.3-10.2-18.112.6-9.1-23.2-57.4-34.9-30.1-35.8-37.389.774.4147.1124.9131.5162.5175.9116.6161.3100.1107.575.150.5-81.60.2-151.6-184.2
000000000000000000000000000000000

Myriad Genetics stock margins

The Myriad Genetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Myriad Genetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Myriad Genetics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Myriad Genetics's sales revenue. A higher gross margin percentage indicates that the Myriad Genetics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Myriad Genetics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Myriad Genetics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Myriad Genetics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Myriad Genetics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Myriad Genetics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Myriad Genetics Margin History

Myriad Genetics Gross marginMyriad Genetics Profit marginMyriad Genetics EBIT marginMyriad Genetics Profit margin
2028e68.64 %9.89 %7.82 %
2027e68.64 %8.01 %6.29 %
2026e68.64 %6.44 %3.76 %
2025e68.64 %2.94 %1.26 %
2024e68.64 %2.44 %1.43 %
202368.64 %-18.18 %-34.96 %
202270.22 %-18.23 %-16.51 %
202171.39 %-18.35 %-3.94 %
202069.51 %-29.29 %-17.71 %
201970.86 %-20.67 %-31.24 %
201876.38 %3.72 %0.54 %
201776.17 %16.39 %17.92 %
201676.51 %6.04 %2.39 %
201578.76 %20.72 %15.83 %
201479.62 %18.56 %11.09 %
201385.97 %35.26 %22.64 %
201287 %37.18 %23.99 %
201186.96 %36.35 %22.62 %
201088.39 %39.24 %25.04 %
200987.81 %37.26 %42 %
200886.77 %38.74 %25.91 %
200785.46 %27.64 %21.44 %
200678.8 %22.23 %-24.09 %
200572.56 %13.82 %-37.97 %
200471.53 %-5.89 %-56.1 %

Myriad Genetics Stock Sales Revenue, EBIT, Earnings per Share

The Myriad Genetics earnings per share therefore indicates how much revenue Myriad Genetics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Myriad Genetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Myriad Genetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Myriad Genetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Myriad Genetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Myriad Genetics Revenue, EBIT and net profit per share

DateMyriad Genetics Sales per ShareMyriad Genetics EBIT per shareMyriad Genetics Earnings per Share
2028e12.52 undefined0 undefined0.98 undefined
2027e11.83 undefined0 undefined0.74 undefined
2026e10.86 undefined0 undefined0.41 undefined
2025e9.95 undefined0 undefined0.13 undefined
2024e9.42 undefined0 undefined0.13 undefined
20239.1 undefined-1.65 undefined-3.18 undefined
20228.42 undefined-1.53 undefined-1.39 undefined
20218.85 undefined-1.62 undefined-0.35 undefined
20204 undefined-1.17 undefined-0.71 undefined
20198.59 undefined-1.78 undefined-2.69 undefined
201811.2 undefined0.42 undefined0.06 undefined
201710.33 undefined1.69 undefined1.85 undefined
201610.59 undefined0.64 undefined0.25 undefined
201510.09 undefined2.09 undefined1.6 undefined
20149.71 undefined1.8 undefined1.08 undefined
20139.95 undefined3.51 undefined2.25 undefined
20127.36 undefined2.74 undefined1.77 undefined
20115.73 undefined2.08 undefined1.3 undefined
20104.38 undefined1.72 undefined1.1 undefined
20093.66 undefined1.36 undefined1.54 undefined
20083.31 undefined1.28 undefined0.86 undefined
20072.39 undefined0.66 undefined0.51 undefined
20061.68 undefined0.37 undefined-0.41 undefined
20051.33 undefined0.18 undefined-0.51 undefined
20041.16 undefined-0.07 undefined-0.65 undefined

Myriad Genetics business model

Myriad Genetics Inc. is a biotechnology company specializing in the research of cancer and genetic analysis technologies. The company was founded in 1991 by Mark Skolnick and has since become a global leader in personalized medicine and diagnostics. It is headquartered in Salt Lake City, Utah, USA, and employs over 2,400 employees worldwide. Myriad Genetics is one of the most popular companies on Eulerpool.com.

Myriad Genetics SWOT Analysis

Strengths

1. Strong Intellectual Property Portfolio: Myriad Genetics Inc possesses a significant number of patents and licenses, providing a competitive advantage in the genetic testing industry.

2. Broad Range of Products and Services: The company offers a comprehensive suite of genetic tests and related services, catering to different medical specialties and patient needs.

3. Established Market Presence: Myriad Genetics Inc has achieved a reputable position in the market, with a long history of delivering reliable genetic testing solutions and gaining the trust of healthcare professionals.

Weaknesses

1. Dependence on Few Key Products: Myriad Genetics Inc relies heavily on a limited number of flagship products, which exposes the company to the risk of market fluctuations and potential loss of market share.

2. Regulatory Challenges: The genetic testing industry is tightly regulated, and changing regulations can impact Myriad Genetics Inc's ability to operate or require costly compliance measures.

3. Limited International Expansion: The company's presence is primarily concentrated in the United States, limiting its potential growth opportunities in international markets.

Opportunities

1. Growing Demand for Genetic Testing: The increasing awareness and importance of personalized medicine present a significant opportunity for Myriad Genetics Inc to expand its customer base and introduce new testing solutions.

2. Advances in Genetic Research: Technological advancements and ongoing research in genetics offer the potential for the development of innovative tests and services, allowing the company to stay ahead of competitors.

3. Strategic Partnerships: Collaborating with pharmaceutical companies, healthcare organizations, and research institutions can provide Myriad Genetics Inc with access to new markets, resources, and expertise.

Threats

1. Competition: The genetic testing industry is becoming increasingly competitive, with the entry of new players and the presence of established companies offering similar services, posing a threat to Myriad Genetics Inc's market share.

2. Reimbursement Challenges: Changes in healthcare policies and reimbursement rates can impact the company's profitability and restrict patient access to genetic testing services.

3. Ethical and Legal Concerns: The handling and interpretation of genetic data raise ethical and privacy concerns, requiring Myriad Genetics Inc to continually address legal and regulatory challenges.

Myriad Genetics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Myriad Genetics Revenue by Segment

Segmente202020192018201720162015201420132011
Molecular diagnostic testing--719.3 M USD------
Molecular diagnostic hereditary cancer testing-479.7 M USD-------
Molecular diagnostic GeneSight testing-112.6 M USD-------
Molecular diagnostic Prenatal testing-104.9 M USD-------
Pharmaceutical and clinical services--53.3 M USD------
Molecular diagnostic Vectra testing-48.3 M USD-------
Molecular diagnostic Prolaris testing-25.5 M USD-------
Molecular diagnostic EndoPredict testing-10.4 M USD-------
Molecular diagnostic other testing-8 M USD-------
Testing Revenue---------
Other revenue---------
Testing revenue---------
Molecular diagnostic revenues---------

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Myriad Genetics Revenue by Segment

Segmente202020192018201720162015201420132011
Molecular diagnostic testing586.9 M USD789.4 M USD-------
Pharmaceutical and clinical services51.7 M USD61.7 M USD-------

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Myriad Genetics Revenue by Segment

Segmente202020192018201720162015201420132011
Molecular diagnostic hereditary cancer testing347.4 M USD--------
Molecular diagnostic Prenatal testing76.7 M USD--------
Molecular diagnostic GeneSight testing74.1 M USD--------
Molecular diagnostic Vectra testing39.1 M USD--------
Molecular diagnostic Prolaris testing24.7 M USD--------
Molecular diagnostic other testing14.4 M USD--------
Molecular diagnostic EndoPredict testing10.5 M USD--------

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Myriad Genetics Revenue by Segment

Segmente202020192018201720162015201420132011
Other45.1 M USD--------

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Myriad Genetics Revenue by Segment

Segmente202020192018201720162015201420132011
Diagnostics593.5 M USD789.4 M USD719.3 M USD722.1 M USD705.7 M USD695.5 M USD---
Molecular Diagnostics------748.2 M USD582.39 M USD400.05 M USD
Other-61.7 M USD53.3 M USD49.3 M USD-----
Other Segments----48.1 M USD27.6 M USD---
Companion Diagnostics-------30.77 M USD2.04 M USD
Pharmaceutical And Clinical Services------30.02 M USD--

Myriad Genetics Revenue by Region

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Myriad Genetics Revenue by Segment

DateRest of worldUnited States
202381.5 M USD671.7 M USD
202286.9 M USD591.5 M USD
202186.9 M USD603.7 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Myriad Genetics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Myriad Genetics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Myriad Genetics shares outstanding

The number of shares was Myriad Genetics in 2023 — This indicates how many shares 82.8 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Myriad Genetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Myriad Genetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Myriad Genetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Myriad Genetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Myriad Genetics stock splits

In Myriad Genetics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Myriad Genetics.

Myriad Genetics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.02 0.06  (204.57 %)2024 Q3
6/30/2024-0.01 0.05  (500 %)2024 Q2
3/31/2024-0.11 -0.01  (90.65 %)2024 Q1
12/31/20230.01 0.04  (207.69 %)2023 Q4
9/30/2023-0.08 -0.03  (63.72 %)2023 Q3
6/30/2023-0.09 -0.08  (7.73 %)2023 Q2
3/31/2023-0.2 -0.21  (-6.49 %)2023 Q1
12/31/2022-0.17 -0.12  (27.97 %)2022 Q4
9/30/2022-0.06 -0.19  (-210.46 %)2022 Q3
6/30/20220.01 0.04  (292.16 %)2022 Q2
1
2

Eulerpool ESG Scorecard© for the Myriad Genetics stock

Eulerpool World ESG Rating (EESG©)

41/ 100

🌱 Environment

35

👫 Social

50

🏛️ Governance

37

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees61
Percentage of women in management
Percentage of Asian employees8
Share of Asian management
Percentage of Hispanic/Latino employees7
Hispano/Latino Management share
Percentage of Black employees4
Black Management Share
Percentage of white employees77
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Myriad Genetics shareholders

%
Name
Stocks
Change
Date
15.05154 % BlackRock Institutional Trust Company, N.A.13,702,92568,5666/30/2024
11.03261 % The Vanguard Group, Inc.10,044,09125,7496/30/2024
9.07560 % Wellington Management Company, LLP8,262,425202,4246/30/2024
6.04130 % Camber Capital Management LP5,500,000-2,135,0006/30/2024
4.83196 % Millennium Management LLC4,399,012-145,1386/30/2024
4.77126 % State Street Global Advisors (US)4,343,757-1,059,9286/30/2024
4.47278 % EARNEST Partners, LLC4,072,018138,9606/30/2024
4.11735 % Glenview Capital Management, LLC3,748,432-1,195,1636/30/2024
3.05026 % Dimensional Fund Advisors, L.P.2,776,95975,4456/30/2024
2.78425 % Artisan Partners Limited Partnership2,534,785-34,9516/30/2024
1
2
3
4
5
...
10

Myriad Genetics Executives and Management Board

Mr. Paul Diaz

(61)
Myriad Genetics President, Chief Executive Officer, Director (since 2020)
Compensation 11.39 M

Mr. Mark Verratti

(54)
Myriad Genetics Chief Commercial Officer
Compensation 2.09 M

Mr. Kevin Haas

(38)
Myriad Genetics Chief Technology Officer
Compensation 1.64 M

Ms. S. Louise Phanstiel

(64)
Myriad Genetics Independent Chairman of the Board
Compensation 561,678

Mr. Daniel Spiegelman

(65)
Myriad Genetics Independent Director
Compensation 449,218
1
2
3
4

Myriad Genetics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Progyny Stock
Progyny
SupplierCustomer0,860,430,850,560,750,89
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,510,36-0,69-0,64-0,83-0,25
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,480,45-0,56-0,74-0,61-0,12
Novartis Stock
Novartis
SupplierCustomer0,470,06-0,83-0,740,100,14
Roche Holding Stock
Roche Holding
SupplierCustomer0,46-0,16-0,60-0,18-0,340,25
Pfizer Stock
Pfizer
SupplierCustomer0,450,08-0,240,36-0,630,34
Illumina Stock
Illumina
SupplierCustomer0,440,230,710,780,890,68
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,270,35-0,61-0,71-0,480,17
Abbott Laboratories Stock
Abbott Laboratories
SupplierCustomer0,260,600,610,720,160,73
Eli Lilly Stock
Eli Lilly
SupplierCustomer0,200,59-0,24-0,54-0,570,61
1

Most common questions regarding Myriad Genetics

What values and corporate philosophy does Myriad Genetics represent?

Myriad Genetics Inc represents values of innovation, dedication to patients, and commitment to improving healthcare through genetic testing and personalized medicine. With a corporate philosophy centered around advancing precision medicine, Myriad Genetics is focused on developing groundbreaking molecular diagnostic tests that enable early detection and prevention of diseases such as cancer. The company aims to empower healthcare professionals and patients with reliable, actionable genetic information to make informed decisions about treatment and preventative measures. Myriad Genetics' dedication to quality, accuracy, and ethical practices makes it a trusted leader in the field of genetic testing and precision medicine.

In which countries and regions is Myriad Genetics primarily present?

Myriad Genetics Inc is primarily present in various countries and regions worldwide. The company has a global presence, with operations and offices in several key locations. Some of the countries and regions where Myriad Genetics Inc is primarily present include the United States, Canada, Europe (including countries like the United Kingdom, France, Germany, Italy, and Spain), Asia Pacific (including countries like Japan, China, and Australia), and Latin America. This widespread presence allows Myriad Genetics Inc to serve a wide range of customers and collaborate with medical professionals and researchers globally.

What significant milestones has the company Myriad Genetics achieved?

Myriad Genetics Inc has achieved several significant milestones throughout its history. One notable achievement is the development of the BRACAnalysis test, which is a groundbreaking genetic test used to identify individuals with a higher risk of developing hereditary breast and ovarian cancer. This test has revolutionized the field of genetic testing and has had a major impact on cancer prevention and treatment. Additionally, Myriad Genetics Inc has successfully expanded its portfolio to include various genetic tests for other diseases, including prostate cancer and hereditary colon cancer. The company continues to innovate and make strides in the field of genetic testing, solidifying its position as a leader in the industry.

What is the history and background of the company Myriad Genetics?

Myriad Genetics Inc is a leading molecular diagnostics company based in the United States. Founded in 1991, the company has a rich history and has made significant contributions to the field of genetic testing and personalized medicine. Myriad Genetics Inc specializes in developing and marketing innovative genetic tests, including those for hereditary cancer and rare diseases. With a strong focus on research and development, the company has established itself as a trusted provider of genetic testing services worldwide. Myriad Genetics Inc's commitment to advancing healthcare through genetic insights has made it a prominent player in the industry.

Who are the main competitors of Myriad Genetics in the market?

The main competitors of Myriad Genetics Inc in the market include companies like Invitae Corporation, Illumina Inc, NeoGenomics Laboratories Inc, and Natera Inc.

In which industries is Myriad Genetics primarily active?

Myriad Genetics Inc is primarily active in the healthcare and biotechnology industries.

What is the business model of Myriad Genetics?

The business model of Myriad Genetics Inc revolves around providing molecular diagnostic tests and genetic analysis services. As a leading molecular diagnostics company, Myriad Genetics focuses on developing and marketing innovative genetic tests for various medical conditions, including cancer and genetic disorders. With a strong emphasis on research and technology, Myriad Genetics aims to improve patient care and outcomes through personalized medicine. By offering a wide range of genetic testing services, the company strives to empower healthcare providers and individuals with valuable genetic insights, enabling more precise diagnosis, treatment decisions, and proactive healthcare management. Myriad Genetics Inc's business model primarily centers on genetic testing for various medical conditions.

What is the P/E ratio of Myriad Genetics 2024?

The Myriad Genetics P/E ratio is 97.37.

What is the P/S ratio of Myriad Genetics 2024?

The Myriad Genetics P/S ratio is 1.39.

What is the Quality Investing of Myriad Genetics?

The Quality Investing for Myriad Genetics is 4/10.

What is the revenue of Myriad Genetics 2024?

The expected Myriad Genetics revenue is 857.59 M USD.

How high is the profit of Myriad Genetics 2024?

The expected Myriad Genetics profit is 12.27 M USD.

What is the business model of Myriad Genetics

The company Myriad Genetics Inc. is a US-American company that specializes in the development and marketing of medical testing procedures and personalized medicine solutions. The business model includes three main divisions: genetic testing, molecular diagnostics, and personalized medicine. In the genetic testing division, Myriad Genetics offers a comprehensive range of genetic tests, including BRCA1 and BRCA2 tests, which are specifically designed to identify the risk of breast cancer in women and men. In addition, the company offers tests for hereditary colon and skin cancer, as well as tests for genetic disorders and hereditary types of cancer. These tests are aimed at providing doctors with a solid basis for making informed decisions, diagnosing accurately, and choosing the best treatment options for their patients. In molecular diagnostics, the company focuses on developing testing procedures specifically designed to identify the genetic basis of certain diseases. Myriad Genetics has developed a wide range of molecular tests that are used in the early detection and treatment of diseases such as breast cancer, colon cancer, and prostate cancer. Personalized medicine reflects the core idea of Myriad Genetics' business model. It involves using a patient's genetics to develop individualized treatment options. The company has developed various technologies tailored to an individual's genetic profile to enable better prediction of the effectiveness of medications and therapies. The goal is to create tailored, targeted treatment methods for patients through personalized medicine and genomic therapies. An important part of Myriad Genetics' business is collaboration with leading researchers, doctors, and medical institutions worldwide. The company has established partnerships with leading oncologists and cancer centers to promote the use of tests and personalized medicine solutions. Additionally, Myriad Genetics has a strong research department that continuously focuses on new technologies and innovative therapies for the treatment of cancer and other serious illnesses. Overall, Myriad Genetics' business model offers a comprehensive range of innovative products and services for the medical community and patients worldwide. The company continuously works to expand and improve its offerings in order to provide the best possible diagnosis and treatment options based on the individual genetic characteristics of each patient.

What is the Myriad Genetics dividend?

Myriad Genetics pays a dividend of 0 USD distributed over payouts per year.

How often does Myriad Genetics pay dividends?

The dividend cannot currently be calculated for Myriad Genetics or the company does not pay out a dividend.

What is the Myriad Genetics ISIN?

The ISIN of Myriad Genetics is US62855J1043.

What is the Myriad Genetics WKN?

The WKN of Myriad Genetics is 897518.

What is the Myriad Genetics ticker?

The ticker of Myriad Genetics is MYGN.

How much dividend does Myriad Genetics pay?

Over the past 12 months, Myriad Genetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Myriad Genetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Myriad Genetics?

The current dividend yield of Myriad Genetics is .

When does Myriad Genetics pay dividends?

Myriad Genetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Myriad Genetics?

Myriad Genetics paid dividends every year for the past 0 years.

What is the dividend of Myriad Genetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Myriad Genetics located?

Myriad Genetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Myriad Genetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Myriad Genetics from 12/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/15/2024.

When did Myriad Genetics pay the last dividend?

The last dividend was paid out on 12/15/2024.

What was the dividend of Myriad Genetics in the year 2023?

In the year 2023, Myriad Genetics distributed 0 USD as dividends.

In which currency does Myriad Genetics pay out the dividend?

The dividends of Myriad Genetics are distributed in USD.

All fundamentals about Myriad Genetics

Our stock analysis for Myriad Genetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Myriad Genetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.